Role of vascular calcification inhibitors in preventing vascular dysfunction and mortality in hemodialysis patients

Semin Dial. 2018 Jan;31(1):72-81. doi: 10.1111/sdi.12616. Epub 2017 Jun 13.

Abstract

Cardiovascular events make up the primary cause of death in hemodialysis patients, and the risk for cardiovascular mortality is significantly increased by vascular calcification, a condition observed frequently in this patient population. The mechanisms underlying the pathogenesis of vascular calcification are complex, and many factors facilitate or hinder the development of calcification. In this review, we first summarize the main factors contributing to the pathogenesis of vascular calcification in patients with end-stage renal disease. We then explore the role of calcification inhibitors in the calcification process, as well as their effect on vascular dysfunction and mortality in hemodialysis patients.

Publication types

  • Review

MeSH terms

  • Cardiotonic Agents / therapeutic use
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / prevention & control*
  • Cause of Death*
  • Female
  • Follow-Up Studies
  • Humans
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / mortality
  • Kidney Failure, Chronic / therapy*
  • Male
  • Osteopontin / therapeutic use
  • Osteoprotegerin / therapeutic use
  • Renal Dialysis / adverse effects*
  • Renal Dialysis / methods
  • Renal Dialysis / mortality
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome
  • Vascular Calcification / drug therapy*
  • Vascular Calcification / etiology*
  • Vascular Calcification / physiopathology
  • alpha-2-HS-Glycoprotein / therapeutic use

Substances

  • Cardiotonic Agents
  • Osteoprotegerin
  • alpha-2-HS-Glycoprotein
  • Osteopontin